Alexza Pharmaceuticals has announced the promotion of Edwin S. Kamemoto, Ph.D., to the newly created position of Senior Vice President, Regulatory Affairs. Dr. Kamemoto will have primary responsibility for leading and directing all regulatory affairs and global pharmacovigilence activities.
Dr. Kamemoto has been Alexza's Vice President, Regulatory Affairs since July 2012. He joined Alexza in 2006 as Associate Director, Regulatory Affairs, was promoted to Director, Regulatory Affairs in 2007, to Senior Director, Regulatory Affairs in 2008, and to Executive Director, Regulatory Affairs in 2010. From 2004 - 2006, Dr. Kamemoto was a consultant for CATO Research, a contract research organization.
From 1995 to 2004, he held various scientific and regulatory affairs managerial positions at Nektar Therapeutics, a publicly traded biopharmaceutical company. He held previous scientific-related positions at Glycomed, Inc. and Celtrix Pharmaceuticals, Inc., both publicly traded biopharmaceutical companies. Dr. Kamemoto received a Ph.D. in biochemistry from UCLA, completed a postdoctoral fellowship at Stanford University and received a B.S. in chemistry and biology from University of Hawaii.